Compositions and method of treating cancer

Abstract

The disclosure provides for compounds of the general structure:and methods of using and compositions comprising the compounds for treating infections, cancer and neoplastic diseases and disorders.

What is claimed is: 
     
       1. A method for inhibiting the growth, migration, proliferation and/or metastasis of a pre-cancer, cancer or neoplastic cell or inhibiting a pathogen, wherein the pre-cancer, cancer or neoplastic cell is selected from the group consisting of melanoma, squamous cell carcinoma, actinic keratosis, keratoacanthoma, and basal cell carcinoma, comprising contacting the cell or pathogen with an inhibiting effective amount of a composition comprising a compound of Formula I(a): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or thereof, wherein,
 N 1 —N 5  are nitrogen atoms; 
 X 1 -X 2  are carbon atoms; 
 the R groups attached by a dashed line are present, or are not present if the R group is connected to an atom that is bound to another atom by a double covalent bond; 
 the bond indicated by both a straight line and a dashed line indicate that the bond may be a single covalent bond or a double covalent bond; 
 the fused heterocyclic ring system comprises three double bonds with N 2  or N 3  forming a double bond and with X 1 , and with N 4  or N 5  forming a double bond with X 2 ; 
 R 1  is a hydroxyl; and 
 R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9  are independently a H, D, or optionally substituted (C 1 -C 3 )-alkyl. 
 
     
     
       2. The method of  claim 1 , wherein the cancer cell is contacted in vivo. 
     
     
       3. The method of  claim 1 , wherein the contacting is through topical administration. 
     
     
       4. The method of  claim 1 , wherein the composition further comprises a chemotherapeutic agent. 
     
     
       5. The method of  claim 1 , wherein the composition is formulated for topical administration. 
     
     
       6. The method of  claim 1 , wherein the composition is formulated for systemic administration. 
     
     
       7. The method of  claim 1 , wherein the composition comprises a commensal probiotic bacteria that produces the compound of Formula I(a), I(b) or II. 
     
     
       8. The method of  claim 7 , wherein the commensal probiotic bacteria expresses 1 or more of the sequences set forth in SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, and/or 55. 
     
     
       9. The method of  claim 7 , wherein the commensal probiotic bacteria comprises  S. epidermidis  strain MO34 and/or MO38.